Reyon Pharmaceutical Co., Ltd. (102460) Stock Statistics & Valuation Metrics

Reyon Pharmaceutical Co., Ltd. has a market cap or net worth of KRW 170.39B. The enterprise value is KRW 396.16B.

Market Cap

KRW 170.39B

Enterprise Value

KRW 396.16B

Reyon Pharmaceutical Co., Ltd. has 18,586,811 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

18,586,811

Owned by Insiders

―

Owned by Institutions

0.33%

Reyon Pharmaceutical Co., Ltd.’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -7.20%.

Return on Equity (ROE)

-0.14

Return on Assets (ROA)

-0.06

Return on Invested Capital (ROIC)

-7.20%

Return on Capital Employed (ROCE)

-0.10

Revenue Per Employee

319.32M

Profits Per Employee

-65.26M

Employee Count

457

Asset Turnover

0.31

Inventory Turnover

2.96

The current PE Ratio of Reyon Pharmaceutical Co., Ltd. is -4.98. Reyon Pharmaceutical Co., Ltd.’s PEG ratio is 0.05.

PE Ratio

-4.98

PS Ratio

1.19

PB Ratio

0.88

Price to FCF

188.26

Price to Operating Cash Flow

28.66

PEG Ratio

0.05

In the last 12 months, Reyon Pharmaceutical Co., Ltd. had revenue of 145.93B and earned -29.83B in profits. Earnings per share was -1604.66.

Revenue

145.93B

Gross Profit

33.76B

Operating Income

-31.57B

Pretax Income

-24.67B

Net Income

-29.83B

EBITDA

228.10M

Earnings Per Share (EPS)

-1604.66

In the last 12 months, operating cash flow was 5.95B and capital expenditures -5.04B, giving a free cash flow of 906.03M billion.

Operating Cash Flow

5.95B

Free Cash Flow

906.03M

Free Cash Flow per Share

49.40

Reyon Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

0.53%

Earnings Yield

-20.02%

Beta

0.15

52-Week Price Change

-13.66%

50-Day Moving Average

9910.20

200-Day Moving Average

10354.60

Relative Strength Index (RSI)

26.48

Average Volume (3m)

31.64K

Reyon Pharmaceutical Co., Ltd. upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 14, 2026

Next Earnings Date

Nov 12, 2026

Ex-Dividend Date

―

Reyon Pharmaceutical Co., Ltd. as a current ratio of 0.56, with Debt / Equity ratio of 98.20%

Current Ratio

0.56

Quick Ratio

0.29

Debt to Market Cap

1.07

Net Debt to EBITDA

918.23

Interest Coverage Ratio

-2.39

In the past 12 months, Reyon Pharmaceutical Co., Ltd. has paid 5.02B in taxes.

Income Tax

5.02B

Effective Tax Rate

-0.20

Reyon Pharmaceutical Co., Ltd. EV to EBITDA ratio is -24.77, with an EV/FCF ratio of 421.48.

EV to Sales

2.66

EV to EBITDA

-24.77

EV to Free Cash Flow

421.48

EV to Operating Cash Flow

64.17

Reyon Pharmaceutical Co., Ltd. has KRW 7.04B in cash and marketable securities with KRW 216.85B in debt, giving a net cash position of -KRW 209.82B billion.

Cash & Marketable Securities

KRW 7.04B

Total Debt

KRW 216.85B

Net Cash

-KRW 209.82B

Net Cash Per Share

-KRW 11.29K

Tangible Book Value Per Share

KRW 10.44K

Gross margin is 21.48%, with operating margin of -20.96%, and net profit margin of -24.02%.

Gross Margin

21.48%

Operating Margin

-20.96%

Pretax Margin

-22.50%

Net Profit Margin

-24.02%

EBITDA Margin

-10.75%

EBIT Margin

-33.04%

The average price target for Reyon Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

-4.45%

EPS Growth Forecast

-250.71%

Smart Score

―

AI Score

44